Compare MasterCard Inc (MA) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Novartis AG — how do they compare? MasterCard Inc trades at $546.79 (market cap $483.71B), while Novartis AG trades at $156 (market cap $290.25B). The key difference: MasterCard Inc is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| MA | NVS | |
|---|---|---|
Market Cap | $483.71B | $290.25B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $168.62 |
52-Week Low | $471.55 | $113.50 |
Enterprise Value | $494.45B | $330.27B |
Dividend Yield | 0.64% | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $543.6, down 1.44% on the day, with strong technical support near $540 and bullish moving average signals. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $4.60 exceeding expectations of $4.41. Revenue grew to $32.79B in 2025, and net income margin remains high at 45.88%. Analysts maintain a strong buy consensus with a $634.27 price target, reflecting 16.7% upside potential.
Outlook remains positive driven by payment volume growth and AI initiatives, but risks include competitive disruption from stablecoins and high valuation multiples. Institutional ownership trends show continued accumulation, supporting bullish sentiment. The stock's current price is within 5% of recent highs, indicating potential for consolidation before further gains.
Novartis (NVS) trades at $149.85, down 2.54% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with $56.67B revenue and $13.98B net income, though recent quarterly EPS results have been mixed. Key developments include FDA approval for Fabhalta and the $1.5B acquisition of Myricx Bio to expand its oncology pipeline.
Outlook remains cautiously optimistic with 68% analyst hold ratings reflecting valuation concerns at 22.03 P/E. Near-term catalysts include Q2 2026 earnings and drug trial readouts, while risks involve pipeline execution and premium valuation pressure. The stock offers stability with robust profitability but faces growth execution tests ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
